These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31630159)

  • 21. Estimating The Cost Of Delayed Generic Drug Entry To Medicaid.
    Dave CV; Sinha MS; Beall RF; Kesselheim AS
    Health Aff (Millwood); 2020 Jun; 39(6):1011-1017. PubMed ID: 32479219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
    Prasad V; Mailankody S
    JAMA Intern Med; 2017 Nov; 177(11):1569-1575. PubMed ID: 28892524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of generic market entry on antibiotic prescriptions in the United States.
    Kållberg C; Hudson J; Salvesen Blix H; Årdal C; Klein E; Lindbæk M; Outterson K; Røttingen JA; Laxminarayan R
    Nat Commun; 2021 May; 12(1):2937. PubMed ID: 34006862
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study.
    Gupta R; Bollyky TJ; Cohen M; Ross JS; Kesselheim AS
    BMJ; 2018 Mar; 360():k831. PubMed ID: 29555641
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recent trends in brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R
    J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Market Exclusivity of the Originator Drugs in South Korea: A Retrospective Cohort Study.
    Son KB
    Front Public Health; 2021; 9():654952. PubMed ID: 33889560
    [No Abstract]   [Full Text] [Related]  

  • 27. Association Between Market Competition and Prices of Generic Topical Dermatology Drugs.
    Li DG; Joyce C; Mostaghimi A
    JAMA Dermatol; 2018 Dec; 154(12):1441-1446. PubMed ID: 30383117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The story of the development of generic lenalidomide: How one company thwarted the Hatch-Waxman Act to generate billions of dollars in revenue.
    Beechinor RJ; Mohyuddin GR; Mitchell DE; Aaron D; Mahmoudjafari Z
    J Cancer Policy; 2023 Dec; 38():100446. PubMed ID: 37777010
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021.
    Luo X; Yang L; Du X; Yang J; Qian F; Yang Y
    Clin Pharmacol Ther; 2022 Aug; 112(2):335-343. PubMed ID: 35485980
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory Incentives for Antibiotic Drug Development: A Review of Recent Proposals.
    Sinha MS; Kesselheim AS
    Bioorg Med Chem; 2016 Dec; 24(24):6446-6451. PubMed ID: 27591793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teva v. Eisai: what's the real "controversy"?
    Wang GL
    Food Drug Law J; 2011; 66(4):631-54, iii. PubMed ID: 24505831
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reductions in Use of Colchicine after FDA Enforcement of Market Exclusivity in a Commercially Insured Population.
    Kesselheim AS; Franklin JM; Kim SC; Seeger JD; Solomon DH
    J Gen Intern Med; 2015 Nov; 30(11):1633-8. PubMed ID: 25855479
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perceived impact of the patent linkage system on pharmaceutical market from the viewpoint of the domestic manufacturers in South Korea.
    Choi N; Son KB; Byun J; Yang DW
    Global Health; 2022 Mar; 18(1):34. PubMed ID: 35313916
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug discovery market exclusivity after KSR: the challenge to pharmaceutical scientists and the US congress.
    Wolff ME
    J Pharm Sci; 2011 Aug; 100(8):3044-3054. PubMed ID: 21472728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trends in Prices of Popular Brand-Name Prescription Drugs in the United States.
    Wineinger NE; Zhang Y; Topol EJ
    JAMA Netw Open; 2019 May; 2(5):e194791. PubMed ID: 31150077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generic Drugs in the United States: Policies to Address Pricing and Competition.
    Gupta R; Shah ND; Ross JS
    Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variations in time of market exclusivity among top-selling prescription drugs in the United States.
    Wang B; Liu J; Kesselheim AS
    JAMA Intern Med; 2015 Apr; 175(4):635-7. PubMed ID: 25664700
    [No Abstract]   [Full Text] [Related]  

  • 38. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Market exclusivity after a prescription to nonprescription drug switch: striking the right balance between innovation and competition.
    Kraushaar KJ
    Food Drug Law J; 1999; 54(2):243-4. PubMed ID: 11758581
    [No Abstract]   [Full Text] [Related]  

  • 40. A new history and discussion of 180-day exclusivity.
    Korn DE; Lietzan E; Scott SW
    Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.